Form 4: 4D Molecular Therapeutics Director Nancy Miller-Rich Granted Stock Options

Nancy Miller-Rich, a Director at 4D Molecular Therapeutics, Inc., was granted 22,500 stock options with an exercise price of $4.15 as part of the company's non-employee director compensation program.

Summary

• Nancy Miller-Rich, a Director of 4D Molecular Therapeutics, Inc. (FDMT), was granted 22,500 stock options.
• The stock options have an exercise price of $4.15 per share.
• The grant date for these options was June 17, 2025.
• The options were automatically granted under the terms of the Company's non-employee director compensation program.
• Vesting for the options begins with 1/3 of the total shares on June 17, 2026, followed by equal monthly installments, with full vesting by June 17, 2028, contingent on continued service.
• The stock options will also fully vest upon the consummation of a Change in Control, as defined in the 2020 Incentive Award Plan.
• The expiration date for these stock options is June 16, 2035.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The grant of stock options to a director is a routine compensation event that aligns interests and incentivizes performance, reflecting standard corporate governance practices. It does not indicate any immediate negative or overwhelmingly positive operational news.

Positives

• The grant of stock options aligns the director's interests with those of shareholders, incentivizing long-term company performance.
• The automatic grant under a compensation program indicates a structured approach to director remuneration.

Risks

• The value of the stock options is dependent on the future stock price of 4D Molecular Therapeutics, Inc., which is subject to market fluctuations and company performance.
• The vesting schedule requires continued service, meaning the director must remain with the company to fully realize the benefit of the options.

Future Outlook

The stock options are designed to incentivize the director's long-term commitment and contribution to the company's growth, with vesting tied to continued service through June 2028 and accelerated vesting upon a change in control.

Industry Context

This transaction is a standard practice in the biotechnology and pharmaceutical industries, where equity compensation, particularly stock options, is commonly used to attract, retain, and incentivize key personnel, including non-employee directors, aligning their interests with long-term shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is a common compensation practice across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule, with a multi-year period and cliff vesting followed by monthly installments, is typical for long-term incentive plans designed to ensure continued commitment.
• The inclusion of a change-in-control clause for accelerated vesting is a standard provision in many equity compensation plans, providing protection and incentive in M&A scenarios.

Corporate Governance

Related Party Transactions

• The grant of stock options to Nancy Miller-Rich, a Director, constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant of options could lead to future dilution if exercised, but also aims to align director incentives with shareholder value creation.
• Employees: No direct impact mentioned, but reflects the company's overall compensation philosophy.
• Director (Nancy Miller-Rich): Receives a significant equity incentive, contingent on company performance and continued service.

Next Steps

• The stock options will begin vesting on June 17, 2026, with 1/3 of the shares becoming exercisable.
• Subsequent vesting will occur in equal monthly installments until full vesting on June 17, 2028.
• The director's continued service to 4D Molecular Therapeutics, Inc. is required for the options to vest.

Key Dates

Keywords

4D Molecular Therapeutics, FDMT, SEC Form 4, stock options, insider transaction, director compensation, equity grant, beneficial ownership, vesting schedule